20/20 Biolabs, Inc. Common Stock Capital Reinvestment Ratio
20/20 Biolabs, Inc. Common Stock capital reinvestment ratio. 20/20 Biolabs, Inc. Common Stock (AIDX) has a Capital Reinvestment Ratio of 0.05x as of December 2022, meaning it reinvests 0% of its operating cash flow ($5.80 Million) in capital expenditures ($261.79K). Check 20/20 Biolabs, Inc. Common Stock cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of 20/20 Biolabs, Inc. Common Stock (2022–2022)
Capital reinvestment ratio of 20/20 Biolabs, Inc. Common Stock from 2022 to 2022. This chart tracks 20/20 Biolabs, Inc. Common Stock's Capital Reinvestment Ratio across 1 annual periods. Also explore AIDX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
20/20 Biolabs, Inc. Common Stock Capital Reinvestment Ratio by Year (2022–2022)
20/20 Biolabs, Inc. Common Stock capital reinvestment ratio by year from 2022 to 2022. For the full cash flow conversion analysis, see how efficiently does 20/20 Biolabs, Inc. Common Stock generate cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.05x | $5.80 Million | $261.79K | — |